#USA #San Francisco #Moon Surgical #AI Surgery #ScoPilot

Moon Surgical's FDA Approval of ScoPilot™: Revolutionizing Intraoperative Surgical Procedures

In a significant advancement in surgical technology, Moon Surgical, a pioneering company in surgical innovation, has announced the FDA approval of its groundbreaking tool, ScoPilot™. This revolutionary AI-powered intraoperative capability is designed to enhance the efficiency and safety of surgical procedures, setting a new benchmark in the healthcare industry.

The Role of NVIDIA Holoscan

Moon Surgical's achievement comes with the integration of NVIDIA Holoscan, a real-time detection platform tailored for the development and deployment of AI applications in the operating room. This technology empowers the Maestro system by Moon Surgical to operate seamlessly during surgical procedures, facilitating safer and more effective outcomes.

Features and Benefits of ScoPilot™

ScoPilot™ is designed to optimize the surgeon's experience, providing exceptional visibility and control throughout the operation. The AI tool enables the laparoscope, connected to the Maestro system, to follow the desired instrument tip with precision. This not only improves the workflow but also allows surgeons to maintain focus without needing to disengage from the instruments in their hands. As a result, surgical procedures can be conducted more smoothly and efficiently.

Anne Osdoit, CEO of Moon Surgical, praised the capabilities of ScoPilot™, stating, "It allows surgeons to manage three instruments with just two hands while ensuring a stable and optimal field of vision crucial during operations." This autonomy for surgeons significantly enhances operating room efficiency, presenting a transformative leap in surgical care.

Expansion of the Maestro System

The Maestro system, for which FDA approval was granted in June 2024, has already demonstrated its versatility, being utilized in over 1,100 surgeries across the USA and Europe. It encompasses various surgical specialties, including general surgery, bariatric procedures, gynecology, and urology. With its advanced environmental detection features, paired with NVIDIA-accelerated computing power, the Maestro system generates extensive surgical datasets, facilitating the evolution of the next generation of physical AI capabilities in the operating room.

As Kimberly Powell, Vice President of Healthcare at NVIDIA, points out, "The software-defined platform of Moon Surgical is a game-changer, continuously pushing boundaries in the surgical robotics industry. ScoPilot™ represents the remarkable achievement of the first FDA-approved AI-driven surgical movement integrated into a robotic platform powered by Holoscan."

The Future Vision of Moon Surgical

Moon Surgical, established in 2020 and headquartered in both Paris and San Francisco, is on a mission to redefine the future of surgical environments. By combining the transformative possibilities offered by the Maestro system and intelligent insights, the company empowers healthcare teams to make informed decisions that ultimately enhance patient care.

The ethos of Moon Surgical revolves around agility and innovation, emphasizing inclusivity, creativity, and collaboration, particularly among its multicultural team members. By continuing to challenge traditional surgical methods, Moon Surgical inspires and innovates in the art of surgery.

For more information about ScoPilot™ and to see how Moon Surgical is shaping the future of surgery, visit www.moonsurgical.com or follow them on LinkedIn.